COMMUNIQUÉS West-GlobeNewswire
-
Femasys Appoints John Moorhead to Board of Directors
30/10/2026 -
Press Release Biocartis NV: Biocartis to Present Initial Development Data for Ultra-Rapid Idylla™ Breast21 Assay at SABCS 2026
30/10/2026 -
Syndax’s Revuforj® (revumenib) Wins Prestigious 2026 Prix Galien USA Award for Best Product for Rare/Orphan Diseases
30/10/2026 -
Akari Therapeutics to Highlight Novel RNA-Splicing ADC Payload Strategy at the 3rd Annual ADC Payload Summit
30/10/2026 -
Pelthos Therapeutics to Combine with Castle Creek Biosciences, Creating Transformative Biotechnology Company Focused on Serious Diseases that Affect the Skin
30/10/2026 -
NeOnc’s Ambitious Brain Cancer Plans are Setting the Stage
30/10/2026 -
Why Kraig Labs’ Spider Silk Could Have a Future in Aerospace
30/10/2026 -
Denali Therapeutics Receives 2026 Prix Galien USA Award for AVLAYAH® (tividenofusp alfa-eknm) as Best Biotechnology Product
30/10/2026 -
Boehringer Ingelheim registers Phase III trial investigating verducatib in COPD
30/10/2026 -
Halloween Peptide Sale 2026: Kylo Peptides Announces $1 Research Vial Sale With Orders of $200 or More
30/10/2026 -
Tangram annonce l’administration du TGM-148 au premier participant de l’essai de phase 1 évaluant le TGM-148, un nouveau médicament expérimental à ARNi contre les troubles hémorragiques
30/10/2026 -
Asia-Pacific is rapidly gaining importance as a major pillar in global life science innovation
30/10/2026 -
Kestra Medical Technologies to Participate in Upcoming Investor Conferences
30/10/2026 -
BrightSpring Health Services, Inc. Reports Third Quarter 2026 Financial Results and Increases Full Year 2026 Guidance
30/10/2026 -
Repligen Announces $1 Billion Private Convertible Senior Notes Transaction
30/10/2026 -
Regeneron Reports Third Quarter 2026 Financial and Operating Results
30/10/2026 -
Agios Announces New PDUFA Goal Date of February 1, 2027, for Mitapivat Sickle Cell Disease sNDA; Company Is Launch-Ready and in Labeling Discussions with FDA
30/10/2026 -
Fractyl Health Strengthens Revita Patent Portfolio as It Advances Toward FDA Submission and Potential Commercialization
30/10/2026 -
NRx Pharmaceuticals (Nasdaq:NRXP) Receives FDA Approval of Preservative-Free Ketamine Ahead of November 10 FDA Goal Date
30/10/2026
Pages